Investigational Avenues in Uncommon EGFR Mutations: NSCLC Tr

Experts share treatment experiences with osimertinib and afatinib, the potential role of immunotherapy, and ongoing investigations with ADCs and emerging TKIs for patients with uncommon EGFR mutations.

Related Keywords

, Precision Medicine , Biomarker Testing , Nsclc , Non Small Cell Lung Cancer , Uncommon Egfr Mutations , Egfr , Osimertinib , Afatinib , Nccn Guidelines , Treatment Sequencing , Immunotherapy , Adcs , Exon 20 Insertions , Biomarker Driven Therapy , Egfr Mutations ,